High fever occurring 4 to 5 days post-transplant of haploidentical bone marrow or peripheral blood stem cells after reduced-intensity conditioning associated with the use of post-transplant cyclophosphamide as prophylaxis for graft-versus-host disease

Biol Blood Marrow Transplant. 2015 Jan;21(1):197-8. doi: 10.1016/j.bbmt.2014.10.008. Epub 2014 Oct 15.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural

MeSH terms

  • Bone Marrow Transplantation / adverse effects
  • Cyclophosphamide / therapeutic use*
  • Fever / etiology
  • Fever / immunology
  • Fever / pathology*
  • Graft vs Host Disease / immunology
  • Graft vs Host Disease / pathology
  • Graft vs Host Disease / prevention & control*
  • Haplotypes*
  • Hematologic Neoplasms / immunology
  • Hematologic Neoplasms / pathology
  • Hematologic Neoplasms / therapy*
  • Histocompatibility Testing
  • Humans
  • Myeloablative Agonists / therapeutic use
  • Peripheral Blood Stem Cell Transplantation / adverse effects*
  • Transplantation Conditioning / methods*
  • Transplantation, Homologous
  • Treatment Outcome
  • Unrelated Donors

Substances

  • Myeloablative Agonists
  • Cyclophosphamide